Last update 16 May 2025

ICT-01

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
ICT01 - ImCheck Therapeutics, ICT 01, ICT-01
Target
Action
inhibitors
Mechanism
BTN3A1 inhibitors(butyrophilin subfamily 3 member A1 inhibitors)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (United States)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory acute myeloid leukemiaPhase 2-11 Sep 2023
Acute Lymphoblastic LeukemiaPhase 2
United States
10 Feb 2020
Acute Lymphoblastic LeukemiaPhase 2
Belgium
10 Feb 2020
Acute Lymphoblastic LeukemiaPhase 2
France
10 Feb 2020
Acute Lymphoblastic LeukemiaPhase 2
Germany
10 Feb 2020
Acute Lymphoblastic LeukemiaPhase 2
Spain
10 Feb 2020
Acute Lymphoblastic LeukemiaPhase 2
United Kingdom
10 Feb 2020
Advanced cancerPhase 2
United States
10 Feb 2020
Advanced cancerPhase 2
Belgium
10 Feb 2020
Advanced cancerPhase 2
France
10 Feb 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
ICT01 10 mg
rcnlcxuoib(shqhbfheku) = All patients had at least one TEAE. Most common Grade 3 or 4 TEAEs were neutropenia (56%), febrile neutropenia (38%), and thrombocytopenia (38%). Grade 3/4 febrile neutropenia for ICT01lowor ICT01highwas seen in 2 (25%) and 5 (63%) patients, respectively. miycgygloj (rgyvbaqptj )
-
08 Dec 2024
ICT01 75 mg
Phase 1
Transitional Cell Carcinoma
BTN3A tumor expression
26
ICT01 7 mg + Pembrolizumab 200 mg
elhqadhxqh(zyxcaxsylp) = 71% itkzgkcvkh (qospajgxkb )
Positive
05 Nov 2024
ICT01 200 mg + Pembrolizumab 200 mg
Phase 1
Refractory Melanoma
BTN3A tumor expression
19
ICT01 2-200 mg + Pembrolizumab 200 mg
epbqjjeazl(ypiaingave) = 31% afpmfdmvfg (wkndpfafrm )
Positive
05 Nov 2024
Phase 1/2
Refractory Melanoma
PD-1 | IFNg | BTN3A ...
35
ICT01 + Pembrolizumab
urrvppjvsu(ttyfvqembl) = gaacfzqxwa hwpxhfqobk (aeqrtdnnfx )
Positive
24 May 2024
Phase 2
-
ICT01 + Venetoclax + Azacitidine
abdxlxcqjg(ktdsrtojiy) = ltggvnyclk rxdyuucblh (whixvarmzs )
-
09 Dec 2023
Phase 1/2
-
dijdkcssev(drohiodofn) = Treatment-related adverse events were mainly mild to moderate infusion-related reactions, comparable to those observed with ICT01 or IL-2 monotherapy ijtgqtjfid (hxvqtpogaa )
Positive
02 Nov 2023
Phase 1/2
26
ayvhbcpwzp(rsixquhxfc) = obfnhsisvy cbfftrgfmo (dnnmiecikg )
Positive
22 Oct 2023
Phase 1/2
9
ujieqcomoa(hpoictutoz) = tgwupqzyvm rthlgeiwaf (zdjodjxwuj )
Positive
14 Apr 2023
Phase 1/2
6
sfwnugdlht(kypmhmdmci) = without any new or increased adverse reactions. nrldvjwgsx (dpkvqxnbwg )
Positive
11 Nov 2022
Phase 1/2
-
bjfuonvdwc(mcpipuhubp) = rapid activation and migration of CD4 and CD8 T cells, NK cells, and granulocytes were observed on day 1 qakgbsxlkz (ggspjtssur )
Positive
07 Nov 2022
ICT01 5mg
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free